vs
Side-by-side financial comparison of LENZ Therapeutics, Inc. (LENZ) and OFF THE HOOK YS INC. (OTH). Click either name above to swap in a different company.
OFF THE HOOK YS INC. is the larger business by last-quarter revenue ($24.0M vs $12.5M, roughly 1.9× LENZ Therapeutics, Inc.). OFF THE HOOK YS INC. runs the higher net margin — -0.3% vs -133.6%, a 133.3% gap on every dollar of revenue. OFF THE HOOK YS INC. produced more free cash flow last quarter ($-867.2K vs $-9.0M).
LENZ Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing novel ophthalmic therapies. Its lead product candidates address presbyopia, the age-related loss of near vision, catering to global patient groups with unmet medical needs in the eye care sector.
LENZ vs OTH — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $24.0M |
| Net Profit | $-16.7M | $-66.7K |
| Gross Margin | — | 12.6% |
| Operating Margin | -151.1% | 1.3% |
| Net Margin | -133.6% | -0.3% |
| Revenue YoY | — | — |
| Net Profit YoY | -63.5% | — |
| EPS (diluted) | $-0.59 | $-0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $12.5M | $24.0M | ||
| Q2 25 | $5.0M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
| Q3 25 | $-16.7M | $-66.7K | ||
| Q2 25 | $-14.9M | — | ||
| Q3 24 | $-10.2M | — | ||
| Q2 24 | $-10.3M | — |
| Q3 25 | — | 12.6% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | -151.1% | 1.3% | ||
| Q2 25 | -337.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | -133.6% | -0.3% | ||
| Q2 25 | -298.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | $-0.59 | $-0.00 | ||
| Q2 25 | $-0.53 | — | ||
| Q3 24 | $-0.38 | — | ||
| Q2 24 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.4M | $2.3M |
| Total DebtLower is stronger | — | $287.2K |
| Stockholders' EquityBook value | $193.9M | $-610.5K |
| Total Assets | $210.7M | $32.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $25.4M | $2.3M | ||
| Q2 25 | $37.6M | — | ||
| Q3 24 | $41.0M | — | ||
| Q2 24 | $84.0M | — |
| Q3 25 | — | $287.2K | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | $193.9M | $-610.5K | ||
| Q2 25 | $206.4M | — | ||
| Q3 24 | $215.3M | — | ||
| Q2 24 | $192.9M | — |
| Q3 25 | $210.7M | $32.6M | ||
| Q2 25 | $217.3M | — | ||
| Q3 24 | $224.0M | — | ||
| Q2 24 | $202.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $-664.2K |
| Free Cash FlowOCF − Capex | $-9.0M | $-867.2K |
| FCF MarginFCF / Revenue | -72.2% | -3.6% |
| Capex IntensityCapex / Revenue | 3.5% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-47.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-8.6M | $-664.2K | ||
| Q2 25 | $-11.5M | — | ||
| Q3 24 | $-10.6M | — | ||
| Q2 24 | $-15.8M | — |
| Q3 25 | $-9.0M | $-867.2K | ||
| Q2 25 | $-11.7M | — | ||
| Q3 24 | $-10.8M | — | ||
| Q2 24 | $-15.9M | — |
| Q3 25 | -72.2% | -3.6% | ||
| Q2 25 | -235.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | 3.5% | 0.8% | ||
| Q2 25 | 4.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
